ELAT - Elanco's Tangible Equity Units: Low-Risk Option With A 5% Yield

• Elanco’s worldwide business, pharmaceuticals, and food additives for pets and farm animals is recession-resistant - and growing rapidly.
• Since the 2018/2019 spin-off from Eli Lilly, Elanco has struggled to gain its operational and financial footing more than the comparable Zoetis.
• Recent acquisitions, i.e., Bayer Animal Health and Kindred Biosciences, are substantial and significant positive developments, but it will take time for consolidation, cost-cutting, synergies, etc. to impact the bottom line.
• Buying ELAT (a Tangible Equity Unit) offers the investor a low-risk option on Elanco’s future with an above-average current yield.

For further details see: